Lisaftoclax (APG-2575)
Sponsors
Ascentage Pharma Group Inc., Ruijin Hospital, The Affiliated People's Hospital of Ningbo University, Peking University First Hospital, Guangdong Second Provincial General Hospital
Conditions
Acute Myeloid Leukemia (AML)Acute Promyelocytic Leukemia (APL)CLL/SLLCutaneous T-Cell Lymphoma/Mycosis FungoidesHigher-risk Myelodysplastic SyndromeMantle Cell Lymphoma (MCL)Myeloid MalignancyPrimary Cutaneous Anaplastic Large Cell Lymphoma
Phase 1
Phase 2
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
RecruitingNCT07272499
Start: 2025-09-10End: 2028-09-10Target: 25Updated: 2026-07-28
Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
Not yet recruitingNCT07597941
Start: 2026-07-01End: 2028-12-01Target: 20Updated: 2026-06-30
Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)
Not yet recruitingNCT07717580
Start: 2026-07-31End: 2028-12-30Target: 46Updated: 2026-07-23
Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure
Enrolling by invitationNCT07813390
Start: 2026-09-01End: 2028-08-31Target: 73Updated: 2026-09-10
Phase 3
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
RecruitingNCT06319456
Start: 2024-04-07End: 2028-08-01Target: 344Updated: 2026-07-28
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
RecruitingNCT06641414
Start: 2025-01-22End: 2029-12-31Target: 490Updated: 2025-11-20